Skip to main content

Advertisement

Table 1 Characteristics of all amplicons used in genotyping assay. Detailed results for individual SNPs within all non-immune loci included in the final assay is provided in the Additional file 1: Tables S1 and S2

From: Development of a SNP-based assay for measuring genetic diversity in the Tasmanian devil insurance population

Amplicon Target variation Chra Length (bp) No. of SNPs No. of SNPs not in HWE No. of haplotypes
AGA Neutral 6 9352 34 2 (6 %) 2
CCLD5/6b Chemokine 4 8209 25 22 (88 %) 18
CX3Cb Chemokine 1 9425 3 1 (33 %) 6
DIG12b NK receptor 3 6351 15 0 (0 %) 3
DIG24b NK receptor 3 6809 1 1 (100 %) 2
DRD5 Dopamine receptor 6 7885 1 0 (0 %) 2
ERN2 Pro-apoptotic 2 10,165 17 17 (100 %) 2
FOXA2 Neutral 1 10,122 39 4 (10 %) 29
IL17Bb Interleukin 1 5717 20 1 (5 %) 2
IL22F1b Interleukin 1 6531 3 2 (67 %) 3
KIT Neutral 2 8356 2 1 (50 %) 3
NF2 Neutral 2 9312 41 1 (2 %) 3
PLEKHM3 Neutral 3 10,034 16 2 (13 %) 5
RAB27A Neutral 1 10,077 2 0 (0 %) 3
TGFB1b Cytokine 3 2649 2 0 (0 %) 3
TLR3b Toll-like receptor 6 7663 32 4 (13 %) 6
UNC13B Neutral 2 9687 14 0 (0 %) 3
Total    138,344 267 58 95
  1. Nb. Amplicons are named according to nearest annotated gene: amplicons are not necessarily targeting the gene they are named for
  2. aChromosome as indicated by Tasmanian devil reference genome v7.1 [32] however recent work has identified that chromosomes 1 and 2 were mis-identified [50]
  3. bIndicates immune-targeted amplicon [40]